Back

Virax Biolabs Group Limited Ordinary Shares

Ticker: VRAX ISIN: KYG9495L1335
Add to portfolio Portfolio analysis in 2min
Stock Large-cap High beta Trading above 200-day average
Market cap
$1.62T
Forward P/E
0.00
Profit margin
0.00%
Revenue growth QoQ
-98.30%
Beta
1.62
$2.82 -4.08%
Price as of 2026-08-28 · NASDAQ

Performance by timeframe

Rolling returns
1 Month -4.08%
6 Months -48.73%
1 Year -80.25%
5 Years -77.20% p.a.-99.94%
Since inception -83.47% p.a.-99.94%
Calendar year returns
YTD -67.40%
2025 -84.62%
2024 +54.11%
2023 -80.00%

Key stats

Market cap
1.62T
Beta
1.62
52-week range
0.35 - 3.20
50-day MA
0.58
200-day MA
0.93
Section 1

Business overview

Company profile data from fundamentals.

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.

Sector Healthcare
Industry Biotechnology
Country United Kingdom
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -1.14%
ROA -64.68%
Profit margin 0.00%
Operating margin -2383.17%
Revenue/share TTM 0.00
Revenue TTM 6.33K
EBITDA -5.91M
Gross profit TTM -53.07K
Beta 1.62

Valuation

Trailing P/E 0.00
Forward P/E 0.00
P/B 0.56
P/S 994.66
EV/EBITDA 0.42
EV/Revenue 54.45
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -1.48
Quarterly earnings growth 0.00%
Revenue TTM 6.33K
Reported quarters 4
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Split factor 1:10
Last split date 2023-12-18
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $3.00
Analyst rating 4

Ownership & short interest

Shares outstanding 4.34M
Shares float 3.68M
Institutional ownership 6.05%
Insider ownership 8.23%
Short ratio 0.20
Short % of float 1.13%

Details

Instrument metadata and source update timestamps.

Symbol VRAX
Name Virax Biolabs Group Limited Ordinary Shares
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN KYG9495L1335
Country USA
Code + exchange VRAX.NASDAQ
Fundamentals updated 2025-12-16

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.